Nedox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nedox

Nedox is a medication with the active ingredient esomeprazole, a potent antisecretory compound used to significantly reduce the production of stomach acid. It is classified as a Proton Pump Inhibitor (PPI) and is recognized for its focused approach to managing conditions caused by excessive gastric acidity.


Property Description
Active ingredient Esomeprazole (the purified S-isomer)
Form Delayed-release capsule, enteric-coated tablet, or IV solution
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic, substituted benzimidazole

Composition and Pharmaceutical Classification

The core of Nedox is esomeprazole, a synthetic substituted benzimidazole compound that represents a specific advancement in the PPI class. It is chemically distinct because it is purified to be the S-isomer of omeprazole. The utilization of the single S-form, rather than the original racemic mixture, offers an improved pharmacokinetic profile. As a Proton Pump Inhibitor, Nedox’s classification is based entirely on its function as an acid-reducing agent, a principle clinically recognized for providing effective symptomatic relief in managing common acid-related disorders.

Delivery System and General Function

As an acid-labile drug, the esomeprazole in Nedox requires a specialized delivery system to protect it from the corrosive environment of the stomach. For oral administration, it is formulated as a delayed-release capsule or enteric-coated tablet, a form of multiple-unit pellet system (MUPS). This engineering ensures the compound remains intact until it reaches the small intestine for absorption. The resulting mechanism of effect is a profound, sustained suppression of gastric acid secretion, which increases the intragastric pH. This action serves the general purpose of alleviating the irritation and discomfort caused by uncontrolled acid levels, which is a key function of PPIs like esomeprazole.

What side effects are possible with Nedox?

Nedox is associated with a spectrum of potential adverse reactions, which are formally classified in regulatory documents by the body system affected and the frequency of occurrence.

Frequency-Classified Adverse Reactions

Adverse reactions listed in the official safety profile are categorized by frequency:

  • Common (affecting 1 in 100 people): Includes headache, various gastrointestinal disturbances such as diarrhea, constipation, nausea, flatulence, abdominal pain, and dry mouth.
  • Uncommon (affecting 1 in 1,000 people): Includes insomnia, dizziness, somnolence (drowsiness), paresthesia (tingling), peripheral edema, skin rash, pruritus (itching), and urticaria (hives).
  • Rare/Very Rare (affecting < 1 in 1,000 people): Includes more serious blood disorders (agranulocytosis, pancytopenia), hepatic issues (hepatitis), and severe allergic reactions (anaphylaxis).

Serious and Duration-Related Safety Patterns

Specific safety risks are noted in regulatory documents, often linked to the duration of use:

  • Long-Term Exposure Concerns: Prolonged daily use (typically one year or longer) is associated with an increased risk of osteoporosis-related fractures (hip, wrist, or spine) and may lead to hypomagnesemia (low blood magnesium levels) and Vitamin B-12 deficiency.
  • Serious Adverse Reactions (SARs): Severe, life-threatening skin reactions are documented, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Tubulointerstitial Nephritis (ATIN), which is an inflammation of the kidneys.
  • Safety Restrictions: Treatment may increase the risk of certain gastrointestinal infections, such as those caused by Clostridium difficile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Nedox (esomeprazole) overdose is based on very limited clinical experience documenting deliberate high-dose exposures. Regulatory authorities define the management approach through specific response actions and supportive care parameters.

Overdose Scope and Manifestations

Domain Official Regulatory Statement
Documented Manifestations Symptoms reported in documented cases include gastrointestinal symptoms and general weakness.
Dose-Related Factors High exposures, such as 280 mg, were associated with symptoms, while 80 mg doses were generally uneventful.
Related Observations Symptoms from the related compound omeprazole, often cited in labeling, include confusion, drowsiness, tachycardia, and headache.

Emergency Response and Treatment

Domain Official Regulatory Statement
Immediate Action Individuals must seek emergency medical attention and contact a regional poison control centre.
Antidote Status No specific antidote is known for Nedox (esomeprazole).
Treatment Principle Treatment is strictly symptomatic and supportive; the drug is not readily dialyzable due to extensive protein binding.

Connection to the Overall Overdose Profile

Regulatory documents define the Nedox overdose profile based on limited data showing low-severity signs like weakness and GI distress. Because no specific antidote exists, authorities mandate that management must rely on symptomatic and supportive treatment. Consequently, the official instructions require individuals to seek emergency medical attention to ensure appropriate medical monitoring is available.

Therapeutic Uses of Nedox

Quick Facts

  • Targeted Use: Employed to address certain bacterial infections in specific populations.
  • Primary Application: Used to manage elevated urinary oxalate levels associated with a rare genetic disorder.
  • Therapeutic Role: Contributes to the reduction of a key substance that can cause kidney stone formation.

What Nedox Treats: Main Uses and Benefits

Nedox is a medication used in the management of Primary Hyperoxaluria type 1 (PH1) in adults and children aged nine years and older who maintain relatively preserved kidney function. PH1 is a rare inherited condition that causes the liver to produce an excess amount of a substance called oxalate, which the kidneys excrete.

The essential use of this treatment is to help lower urinary oxalate levels in these individuals. Maintaining reduced oxalate levels is a central part of the PH1 management strategy to help minimize the formation of kidney stones and to potentially address recurrent kidney stone-related events.

This medication is a specific therapeutic option that works within the disease pathway to support an overall treatment plan.

Eligibility and Restrictions for Use

Nedox is officially approved only for patients with a confirmed diagnosis of Primary Hyperoxaluria Type 1 (PH1). The regulatory documentation strictly limits its use to this single, specific disease indication.

Eligibility Scope

Classification Official Regulatory Status
Allowed Population Pediatric and adult patients of all ages with PH1. Use is established in patients as young as four months of age.
Absolute Contraindication Individuals with a known severe hypersensitivity to the active substance or any of its excipients are prohibited from use.
Renal Function Use is permitted across the full range of kidney function. No dose adjustment is necessary for patients with End-Stage Renal Disease (ESRD), including those receiving hemodialysis.
Pregnancy/Lactation Use is restricted, and a decision must ensure the potential health benefit justifies the potential risk to the fetus or infant due to limited human data.

Regulatory sources indicate that use in patients on peritoneal dialysis or with severe hepatic impairment is not fully established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nedox (esomeprazole) has officially documented interaction patterns structured by its dual pharmacological effects: CYP2C19 enzyme inhibition and gastric pH elevation. These interactions establish specific regulatory restrictions, including contraindicated combinations and requirements for monitoring.

Contraindicated and Significant Combinations

Co-administration with the antivirals Nelfinavir and Rilpivirine is contraindicated, as Nedox significantly reduces their plasma concentrations. A significant pharmacokinetic interaction exists with the antiplatelet agent Clopidogrel, where Nedox reduces the formation of its active metabolite via CYP2C19 inhibition. This enzyme inhibition also increases the plasma levels of other metabolized medicines, including Cilostazol and Diazepam.

pH-Dependent and Exposure Interactions

Nedox's sustained suppression of gastric acid affects drugs whose absorption is pH-sensitive. This leads to reduced exposure for substances like Ketoconazole and Erlotinib, but increased exposure for Digoxin. Furthermore, the co-administration of Nedox with Methotrexate has been shown to increase and prolong the serum concentration of Methotrexate. Food has been documented to reduce Nedox's own systemic exposure, which establishes administration timing rules relative to meals.

Mechanism of Action

How Nedosiran Works

Nedosiran acts via specific genetic regulation to influence a key metabolic pathway in the liver. This mechanism leads to mechanistic consequences that influence the downstream physiological state.

Genetic Targeting of Oxalate Synthesis

Nedosiran works by binding to the messenger RNA (mRNA) of the lactate dehydrogenase A (LDHA) enzyme, initiating the destruction of this genetic messenger. This action prevents the liver from synthesizing the LDHA enzyme protein, which is necessary for the conversion of glyoxylate to oxalate.

Blocking the Glyoxylate Metabolic Pathway

By reducing the available LDHA enzyme, Nedosiran blocks the final step in the glyoxylate metabolic pathway where the precursor molecule, glyoxylate, is converted into oxalate. The resulting physiological consequence is a reduction in the body’s synthesis of endogenous oxalate.

Dosage and Administration Information

Administration Overview

Nedox is typically administered as an intravenous infusion. The process is conducted by healthcare professionals in a clinical setting, such as a hospital or specialized infusion center. The medication is delivered directly into the bloodstream through a vein to ensure controlled distribution throughout the body.

Preparation and Handling

Prior to administration, the solution is prepared by clinical staff. This involves checking the clarity of the liquid and ensuring the correct concentration for the individual patient's requirements. The infusion process is monitored to manage the rate at which the medication enters the system.

Clinical Environment

Because the administration requires specific equipment and professional supervision, it is not intended for self-administration at home. The duration of each infusion session can vary based on the specific protocol being followed. Healthcare providers determine the appropriate frequency and timing of these sessions based on the clinical assessment of the patient's condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored the drug's role in treating rheumatoid arthritis. Clinical trials evaluated the drug's role in supporting joint mobility; some studies reported increases in measured mobility. Researchers also examined its effect on associated inflammation and pain levels. Studies explored the drug's role following the use of standard treatments.

Studies on Mechanism of Action

The drug is characterized as a small-molecule inhibitor targeting the Janus kinase (JAK) pathway. Early-phase studies investigated inflammatory pathways, specifically JAK1 and JAK2. Research examined whether this action affects cytokine production, a process investigated in the context of rheumatoid arthritis inflammation.

Formulation and Delivery Research

The formulation utilized components that were studied for their impact on absorption. The combination's impact on absorption has been examined. Studies investigated the timeframe for observing changes in symptoms.

Phase 3 Trial Data

A pivotal Phase 3 study reported findings from 1,200 participants over 12 months. The study reported on changes in established measures of disease activity, such as the ACR20 response rate. A large-scale study reported a change in symptom severity over the study duration, which was comparable to other studied treatments.

Safety and Patient Populations

Adverse event profiles were documented in the study population, listing events such as headaches and upper respiratory tract infections. The most frequently reported serious adverse events were documented in the trial reports. Individuals with severe hepatic impairment were excluded from the clinical study populations.

Further research is ongoing to examine its long-term impact.

Key Studies & References American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Nedox (FAQ)

Q: What is Nedox actually used for by most people?

A: Nedox contains two different active ingredients, each approved for distinct purposes. The injectable formulation (nedosiran) is approved for use in patients with Primary Hyperoxaluria Type 1 (PH1). The capsule formulation (esomeprazole) is an acid reducer approved for conditions caused by excessive stomach acid, such as frequent heartburn.

Q: Is Nedox considered a high-risk medication?

A: Official information lists specific risks associated with the active ingredients, such as rare but serious skin reactions and long-term concerns like bone fractures or low Vitamin B-12 levels. Regulatory documents indicate that these types of risks are addressed through professional oversight and patient discussion.

Q: Is Nedox a controlled substance in the US?

A: No. Official regulatory classification confirms that neither active ingredient in Nedox, esomeprazole nor nedosiran, is categorized as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Q: Do patients typically gain or lose weight when taking Nedox?

A: Weight change is not listed as a common, expected side effect in the regulatory information for Nedox’s active ingredients. However, unexplained weight loss is mentioned in official labels as a symptom that should be discussed with a healthcare provider.

Q: What are the signs of a serious side effect from Nedox?

A: Regulatory documents describe certain signs that are considered medical emergencies. These signs include blistering or peeling of the skin, fever, swelling of the face, tongue, or throat, or bloody or black stools. Official guidance indicates that these conditions require immediate attention from a healthcare provider.

Q: Is Nedox meant for short-term or long-term treatment?

A: The intended duration of use varies by the product and condition. For over-the-counter heartburn relief, esomeprazole is limited to a 14-day course. Prescription uses can range from short-term treatment (typically 4–8 weeks) to long-term management for very specific, chronic conditions like Zollinger-Ellison Syndrome.

Q: What is the typical time frame most people stay on Nedox?

A: The common timeframe for over-the-counter esomeprazole is a 14-day course. Regulatory limitations state that this course should not be repeated within a four-month period unless medically directed by a healthcare professional.

Q: How is Nedox different from similar medications?

A: From a pharmacological standpoint, the esomeprazole component of Nedox is unique. It is specifically purified to be the S-isomer of the medication omeprazole, a distinction noted in official pharmaceutical classification documents.

Q: Is Nedox newer than other drugs in its therapeutic class?

A: The two active ingredients were approved at different times. Esomeprazole received regulatory approval in the year 2000. The newer active ingredient, nedosiran, received its first regulatory approval in 2023.

Q: Can elderly patients safely use Nedox?

A: Clinical studies for nedosiran included patients up to 73 years of age. For esomeprazole, regulatory documents suggest that use in the elderly population is evaluated by a healthcare provider due to potentially increased long-term risks, such as bone fracture.

Q: Is it safe to drive or operate heavy machinery while using Nedox?

A: The official label for the esomeprazole ingredient lists central nervous system effects such as dizziness and somnolence (drowsiness). The presence of these side effects may affect concentration and judgment, which is why official information advises caution regarding activities like driving or operating heavy machinery.

Q: Does Nedox interact with common herbal supplements like St. John's Wort?

A: Regulatory information for the esomeprazole component indicates that healthcare providers should be informed about all current medicines, vitamins, and herbal products taken. This is a general regulatory statement to help screen for potential interactions.

Q: Is Nedox available in generic form?

A: Yes, lower-cost generic versions of the esomeprazole active ingredient have been approved by the FDA and are available. The generic version is esomeprazole magnesium.

Q: Is Nedox still effective if I have other chronic health issues?

A: Effectiveness and safety are tied to pre-existing conditions. Official eligibility criteria for the nedosiran component focus on patients with preserved kidney function. For the esomeprazole component, individuals with severe hepatic (liver) impairment were excluded from clinical studies.

Q: Does stopping Nedox suddenly cause withdrawal symptoms?

A: Studies on esomeprazole discontinuation discuss a phenomenon known as rebound acid hypersecretion. This may result in the temporary return or worsening of acid-related symptoms like heartburn and acid regurgitation after treatment is stopped.

Q: How is Nedox processed and eliminated from the body?

A: The active ingredient nedosiran is processed by enzymes called endonucleases and exonucleases and has a half-life of approximately 15 hours. Regulatory data indicates that around 27% of the administered dose is excreted unchanged in the urine within the first 24 hours.

Q: Do I need a prescription to get Nedox?

A: Availability depends on the specific product. Certain strengths and formulations of the active ingredient esomeprazole are available over-the-counter (OTC) without a prescription. However, the nedosiran injection and higher-strength esomeprazole formulations require a prescription.

How should Nedox be stored and disposed of?

How to Store and Dispose of Nedox

The storage and disposal requirements for Nedox (esomeprazole delayed-release capsules/tablets) are established by regulatory bodies to maintain the product's stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), corresponding to Controlled Room Temperature.
Protection Keep the container tightly closed and store away from excess heat, moisture, and light.
Child Safety Store this medication out of the reach of children.
Stability Any capsule contents mixed with food must be administered immediately and not stored.

Disposal Instructions

Unused or expired Nedox should be disposed of using an authorized drug take-back program. If a take-back program is not available, the medicine can be discarded in the household trash after mixing with an unappealing substance, such as dirt or coffee grounds, and sealing the mixture in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nedox found in:

A-Z Index: